{"id":"calcium","rwe":[{"pmid":"41913078","year":"2026","title":"Stinging nettle leaf powder: Functional, nutritional, antinutritional qualities and acceptability of a developed savoury snack.","finding":"","journal":"Journal of the science of food and agriculture","studyType":"Clinical Study"},{"pmid":"41913003","year":"2026","title":"Mechanical performance optimization of CaCO₃-modified fly ash-based hybrid geopolymer concrete using Taguchi methodology.","finding":"","journal":"Environmental science and pollution research international","studyType":"Clinical Study"},{"pmid":"41912823","year":"2026","title":"Calcium Signaling Modulator 4-MPTC Reduces Proliferative and Migration Activities of MDA-MB-468 Breast Cancer Cells.","finding":"","journal":"Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections","studyType":"Clinical Study"},{"pmid":"41912655","year":"2026","title":"Repurposing lurasidone to alleviate doxorubicin-induced cardiotoxicity and neurotoxicity via BDNF/TrkB/PI3K/Akt/CREB and miR-34a-5p/PGC-1α pathways.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"41912643","year":"2026","title":"Using machine learning algorithms to predict MACE in peritoneal dialysis patients.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"_fda":{"id":"7749772b-1a26-4b2e-b97d-3ee29611d035","set_id":"000c044a-12ef-4484-942e-99552b777d58","openfda":{"unii":["Y882YXF34X"],"route":["ORAL"],"rxcui":["359296"],"spl_id":["7749772b-1a26-4b2e-b97d-3ee29611d035"],"brand_name":["Calcium Acetate"],"spl_set_id":["000c044a-12ef-4484-942e-99552b777d58"],"package_ndc":["69097-862-03","69097-862-83"],"product_ndc":["69097-862"],"generic_name":["CALCIUM ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CALCIUM ACETATE"],"manufacturer_name":["Cipla USA Inc.,"],"application_number":["ANDA203135"],"is_original_packager":[true]},"version":"6","pregnancy":["8.1 Pregnancy Pregnancy Category C Calcium acetate capsules contain calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see Warnings and Precautions (5.1) ] . Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment."],"overdosage":["10 OVERDOSAGE Administration of calcium acetate in excess of the appropriate daily dosage may result in hypercalcemia [see Warnings and Precautions (5.1) ]."],"description":["11 DESCRIPTION Calcium acetate acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is C 4 H 6 CaO 4 , and its molecular weight is 158.17. Its structural formula is: Each capsule is of size ‘00el’ hard gelatin capsule shell with blue opaque cap and white opaque body imprinted with “667 mg” on cap and “IG 377” on body in black ink filled with white to off white powder. Each capsule contains 667 mg calcium acetate, USP (anhydrous; Ca(CH 3 COO) 2 ; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium. Each capsule contains the following inactive ingredients: Sodium Lauryl Sulfate and Sodium Stearyl Fumarate. The gelatin cap and body have the following inactive ingredients: FD&C blue #1, FD&C red #3, titanium dioxide, USP, gelatin, USP and iron oxide black. Calcium acetate capsules, USP are administered orally for the control of hyperphosphatemia in end stage renal failure. “the drug product meets USP Dissolution Test 4” calcium acetate Chemical structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Each capsule is of size ‘00el’ hard gelatin capsule shell with blue opaque cap and white opaque body imprinted with “667 mg” on cap and “IG 377” on body in black ink filled with white to off white powder. Supplied in Bottles of 60 (NDC 69097-862-03) and 200 (NDC 69097-862-83). STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20210601","nursing_mothers":["8.3 Nursing Mothers A calcium acetate capsule contains calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored."],"clinical_studies":["14 CLINICAL STUDIES Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid oral dosage form. Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following a 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study. The patients received calcium acetate 667 mg tablets at each meal for a period of 12 weeks. The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain. The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented. Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim, and Study Completion Time Points Parameter Pre-Study Week 4 b Week 8 Week 12 p-value c Phosphorus (mg/dL) a 7.4 ± 0.17 5.9 ± 0.16 5.6 ± 0.17 5.2 ± 0.17 ≤0.01 Calcium (mg/dL) a 8.9 ± 0.09 9.5 ± 0.10 9.7 ± 0.10 9.7 ± 0.10 ≤0.01 a Values expressed as mean ± SE. b Ninety-one patients completed at least 6 weeks of the study. c ANOVA of difference in values at pre-study and study completion. There was a 30% decrease in serum phosphorus levels during the 12 week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study. Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks. The phosphate binding effect of calcium acetate is shown in the Table 3. Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and After Completion of Each Treatment Arm Parameter Pre-Study Post-Treatment p-value b Calcium Acetate Placebo Phosphorus (mg/dL) a 7.3 ± 0.18 5.9 ± 0.24 7.8 ± 0.22 <0.01 Calcium (mg/dL) a 8.9 ± 0.11 9.5 ± 0.13 8.8 ± 0.12 <0.01 a Values expressed as mean ± SEM. b ANOVA of calcium acetate vs. placebo after 2 weeks of treatment. Overall, 2 weeks of treatment with calcium acetate statistically significantally (p<0.01) decreased serum phosphorus by a mean of 19% and increased serum calcium by a statistically significant (p<0.01) but clinically unimportant mean of 7%."],"pharmacodynamics":["12.2 Pharmacodynamics Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions."],"adverse_reactions":["6 ADVERSE REACTIONS Hypercalcemia is discussed elsewhere [see Warnings and Precautions (5.1) ]. The most common (>10%) adverse reactions are hypercalcemia, nausea and vomiting. ( 6.1 ) In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical studies, calcium acetate has been generally well tolerated. Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1. Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis Preferred Term Total adverse reactions reported for calcium acetate n=167 n (%) 3-month, open-label study of calcium acetate n=98 n (%) Double blind, placebo-controlled, cross-over study of liquid calcium acetate n=69 Calcium acetate n (%) Placebo n (%) Nausea 6 (3.6) 6 (6.1) 0(0.0) 0(0.0) Vomiting 4 (2.4) 4 (4.1) 0(0.0) 0(0.0) Hypercalcemia 21 (12.6) 16 (16.3) 5 (7.2) 0(0.0) Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate - induced hypercalcemia. Isolated cases of pruritus have been reported, which may represent allergic reactions. 6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure. The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness."],"contraindications":["4 CONTRAINDICATIONS Patients with hypercalcemia. Hypercalcemia. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism. There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs. When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate. Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones. ( 7 ) When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug. ( 7 ) 7.1 Ciprofloxacin In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%."],"labor_and_delivery":["8.2 Labor and Delivery The effects of calcium acetate on labor and delivery are unknown."],"mechanism_of_action":["12.1 Mechanism of Action Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD. 12.1 Mechanism of Action Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. 12.2 Pharmacodynamics Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions."],"indications_and_usage":["1 INDICATIONS AND USAGE Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Treat mild hypercalcemia by reducing or interrupting calcium acetate capsules and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate capsules. ( 5.1 ) Hypercalcemia may aggravate digitalis toxicity. ( 5.2 ) 5.1 Hypercalcemia Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium based nonprescription antacids, concurrently with calcium acetate. An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia. More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well. Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined. Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment. Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg 2 /dL 2 . 5.2 Concomitant Use with Medications Hypercalcemia may aggravate digitalis toxicity."],"clinical_studies_table":["
Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim, and Study Completion Time Points
ParameterPre-StudyWeek 4 bWeek 8Week 12p-valuec
Phosphorus (mg/dL) a7.4 ± 0.175.9 ± 0.165.6 ± 0.175.2 ± 0.17≤0.01
Calcium (mg/dL) a8.9 ± 0.099.5 ± 0.109.7 ± 0.109.7 ± 0.10≤0.01
","
Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and After Completion of Each Treatment Arm
ParameterPre-StudyPost-Treatmentp-valueb
Calcium AcetatePlacebo
Phosphorus (mg/dL)a7.3 ± 0.185.9 ± 0.247.8 ± 0.22<0.01
Calcium (mg/dL)a8.9 ± 0.119.5 ± 0.138.8 ± 0.12<0.01
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment and Fertility No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate."],"adverse_reactions_table":["
Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis
Preferred TermTotal adverse reactions reported for calcium acetaten=167n (%)3-month, open-label study of calcium acetaten=98n (%)Double blind, placebo-controlled, cross-over study of liquid calcium acetaten=69
Calcium acetaten (%)Placebon (%)
Nausea6 (3.6)6 (6.1)0(0.0)0(0.0)
Vomiting4 (2.4)4 (4.1)0(0.0)0(0.0)
Hypercalcemia21 (12.6)16 (16.3)5 (7.2)0(0.0)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients to take calcium acetate with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after calcium acetate. Manufactured by: Avema Pharma Solutions 10400 NW 29th Terrace, Doral, FL 33172 Manufactured for: Cipla USA, Inc. 10 Independence Boulevard, Suite 300 Warren, NJ 07059 Revised: 06/2021 Barcode: 862-06-2021"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended initial dose of calcium acetate for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 capsules with each meal. Starting dose is 2 capsules with each meal. (2) Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached. Most patients require 3-4 capsules with each meal. (2)"],"spl_product_data_elements":["Calcium Acetate Calcium Acetate CALCIUM ACETATE CALCIUM CATION SODIUM LAURYL SULFATE SODIUM STEARYL FUMARATE FD&C BLUE NO. 1 FD&C RED NO. 3 TITANIUM DIOXIDE GELATIN, UNSPECIFIED FERROSOFERRIC OXIDE blue opaque cap and white opaque body hard gelatin capsule shell 667mg;IG377"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Capsule: 667 mg calcium acetate per capsule. Capsule: 667 mg calcium acetate capsules. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category C Calcium acetate capsules contain calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see Warnings and Precautions (5.1) ] . Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. 8.2 Labor and Delivery The effects of calcium acetate on labor and delivery are unknown. 8.3 Nursing Mothers A calcium acetate capsule contains calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"package_label_principal_display_panel":["undefined NDC 69097-862-83 R x Only Calcium Acetate Capsules, USP 667 mg* 200 Capsules Cipla Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment and Fertility No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Solution","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"},{"label":"end stage renal disease","category":"indication"},{"label":"end stage renal disease","category":"indication"},{"label":"Fresenius Medcl Care","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"38474 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"34727 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"32487 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"31877 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"28629 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"27921 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"27246 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"25867 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"24189 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"23601 reports"}],"drugInteractions":[{"url":"/drug/tetracyclines","drug":"Tetracyclines","action":"Avoid","effect":"decrease bioavailability","source":"OpenFDA Label","drugSlug":"tetracyclines"},{"url":"/drug/fluoroquinolones","drug":"Fluoroquinolones","action":"Avoid","effect":"decrease bioavailability","source":"OpenFDA Label","drugSlug":"fluoroquinolones"},{"url":"/drug/ciprofloxacin","drug":"Ciprofloxacin","action":"Avoid","effect":"decrease bioavailability by approximately 50%","source":"OpenFDA Label","drugSlug":"ciprofloxacin"},{"url":"/drug/anti-arrhythmic-medications","drug":"Anti-arrhythmic medications","action":"Use caution","effect":"unknown","source":"OpenFDA Label","drugSlug":"anti-arrhythmic-medications"},{"url":"/drug/anti-seizure-medications","drug":"Anti-seizure medications","action":"Use caution","effect":"unknown","source":"OpenFDA Label","drugSlug":"anti-seizure-medications"}],"commonSideEffects":[{"effect":"Hypercalcemia","drugRate":"12.6%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"6.1%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"4.1%","severity":"common","_validated":true},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Edema","drugRate":"reported","severity":"unknown"},{"effect":"Weakness","drugRate":"reported","severity":"unknown"}],"contraindications":["Patients with hypercalcemia"],"specialPopulations":{"Lactation":"Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.","Pregnancy":"Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment. Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.","Geriatric use":"Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment."}},"trials":[],"aliases":[],"company":"Fresenius Medcl Care","patents":[{"applNo":"N022581","source":"FDA Orange Book","status":"Active","expires":"Jul 20, 2027","useCode":"U-1469","territory":"US","drugProduct":false,"patentNumber":"8592480","drugSubstance":false},{"applNo":"N022581","source":"FDA Orange Book","status":"Active","expires":"Jul 20, 2027","useCode":"U-1469","territory":"US","drugProduct":false,"patentNumber":"9089528","drugSubstance":false},{"applNo":"N022581","source":"FDA Orange Book","status":"Active","expires":"Feb 23, 2030","useCode":"U-1469","territory":"US","drugProduct":true,"patentNumber":"8591938","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CALCIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:25:28.548445+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:25:28.542053+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:25:35.098699+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:25:27.123331+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:25:35.882640+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:25:24.661586+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:25:24.661638+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:25:37.850201+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200668/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:25:36.710988+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203135","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:25:24.661645+00:00"}},"allNames":"calcium acetate","offLabel":[],"synonyms":["Calcium Acetate","CALCIUM ACETATE"],"timeline":[{"date":"1990-12-10","type":"positive","source":"FDA Orange Book","milestone":"Phoslo approved — 667MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2001-04-02","type":"positive","source":"FDA Orange Book","milestone":"Phoslo approved — 333.5MG"},{"date":"2011-04-13","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"},{"date":"2022-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Fresenius Kabi Usa to Fresenius Medcl Care"},{"date":"20220218","type":"positive","source":"OpenFDA","milestone":"FDA approval (Fresenius Kabi Usa)"}],"aiSummary":"Calcium Acetate is a small molecule medication developed by Fresenius Kabi USA and currently owned by Fresenius Medical Care. It was FDA-approved in 2022 for the treatment of end-stage renal disease. The commercial status of Calcium Acetate is generic, with 13 generic manufacturers available. Key safety considerations include monitoring of serum calcium levels and potential interactions with other medications. Calcium Acetate is used to manage low calcium levels in patients with end-stage renal disease.","approvals":[{"date":"20220218","orphan":false,"company":"FRESENIUS KABI USA","regulator":"FDA"}],"brandName":"Calcium Acetate","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.","oneSentence":"Calcium Acetate works by providing supplemental calcium to the body, which is essential for various bodily functions including muscle and nerve function.","technicalDetail":"Calcium Acetate is a calcium salt that provides supplemental calcium ions to the body, which are then absorbed and utilized by cells to support various physiological processes, including muscle contraction, nerve transmission, and bone mineralization."},"commercial":{"launchDate":"2022","_launchSource":"OpenFDA (20220218, FRESENIUS KABI USA)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"CALCIUM\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"CALCIUM\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=calcium","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=calcium","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:36:04.963021","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:25:44.661182+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"calcium","indications":{"approved":[{"name":"end stage renal disease","source":"OpenFDA Label","regulator":"FDA"},{"name":"end stage renal disease","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Fresenius Medcl Care","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT04345614","phase":"PHASE2","title":"A Study of Auxora in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"CalciMedica, Inc.","startDate":"2020-04-08","conditions":["Pneumonia"],"enrollment":314,"completionDate":"2021-07-30"},{"nctId":"NCT04747912","phase":"PHASE2","title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","status":"SUSPENDED","sponsor":"University of Chicago","startDate":"2021-03-02","conditions":["Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia","ph+ Acute Lymphoblastic Leukemia"],"enrollment":25,"completionDate":"2027-03-01"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":["Colon Adenocarcinoma","Rectal Adenocarcinoma"],"enrollment":477,"completionDate":"2030-10-27"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":["Metastatic Colorectal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7"],"enrollment":120,"completionDate":"2027-06-01"},{"nctId":"NCT07501078","phase":"PHASE2","title":"Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation","status":"NOT_YET_RECRUITING","sponsor":"Muhammad N Aslam, MD","startDate":"2026-05","conditions":["Ulcerative Colitis","Ileal Pouch"],"enrollment":52,"completionDate":"2029-05"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT07240246","phase":"NA","title":"Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation","startDate":"2025-10-24","conditions":["GLP-1","Obesity &Amp; Overweight","Dietary Supplement"],"enrollment":40,"completionDate":"2026-05-11"},{"nctId":"NCT02366819","phase":"PHASE4","title":"Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer","status":"SUSPENDED","sponsor":"University of Chicago","startDate":"2014-12-11","conditions":["Esophageal Adenocarcinoma","Gastric Adenocarcinoma","Stage IIB Gastric Cancer","Stage IIIA Esophageal Adenocarcinoma","Stage IIIA Gastric Cancer","Stage IIIB Esophageal Adenocarcinoma","Stage IIIB Gastric Cancer","Stage IIIC Esophageal Adenocarcinoma","Stage IIIC Gastric Cancer"],"enrollment":36,"completionDate":"2026-06-08"},{"nctId":"NCT05953376","phase":"PHASE3","title":"Empiric Calcium in Massive Transfusion","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2025-01","conditions":["Hemorrhage","Trauma","Hypocalcemia","Shock, Hemorrhagic"],"enrollment":0,"completionDate":"2026-12"},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":["Advanced Biliary Tract Carcinoma","Advanced Gallbladder Carcinoma","Advanced Intrahepatic Cholangiocarcinoma","Recurrent Biliary Tract Carcinoma","Recurrent Gallbladder Carcinoma","Recurrent Intrahepatic Cholangiocarcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Carcinoma","Unresectable Gallbladder Carcinoma","Unresectable Intrahepatic Cholangiocarcinoma"],"enrollment":66,"completionDate":"2026-05-01"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":["Metastatic Colorectal Adenocarcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Adenocarcinoma"],"enrollment":24,"completionDate":"2026-12-31"},{"nctId":"NCT07105930","phase":"NA","title":"Trial to Assess Non-inferiority of an Orbital Atherectomy Only Versus a Calcium-tailored Debulking Approach","status":"RECRUITING","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","startDate":"2025-10-30","conditions":["Orbital Atherectomy"],"enrollment":310,"completionDate":"2027-03"},{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":["Diabetes Mellitus","High Blood Pressure","Cardiovascular Diseases","Cognitive Impairment"],"enrollment":9476,"completionDate":"2026-05-31"},{"nctId":"NCT06018831","phase":"NA","title":"Urine and Ultrasound Screening for Kidney Disease in Children","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-04-12","conditions":["Kidney Diseases","Diagnostic Techniques","Ultrasound","Urinalysis","Child, Only"],"enrollment":13000,"completionDate":"2028-02"},{"nctId":"NCT07196683","phase":"NA","title":"Regenerative Potentials of Mature Mandibular Molars With Symptomatic Irreversible Pulpitis Enhanced With Different Scaffolds","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-07-01","conditions":["Symptomatic Irreversible Pulpitis (SIP)"],"enrollment":36,"completionDate":"2027-11-01"},{"nctId":"NCT07396688","phase":"NA","title":"Comparative Evaluation of the Effects of Calcium Hydroxide and BIO-C Temp Medicaments on Postoperative Pain in Patients Undergoing Endodontic Treatment: a Clinical Study","status":"RECRUITING","sponsor":"Ankara University","startDate":"2026-03-25","conditions":["Postoperative Pain","Medicaments Substances in Therapeutic Use","Calcium Hydroxide","Root Canal Retreatment"],"enrollment":60,"completionDate":"2026-04-15"},{"nctId":"NCT06867068","phase":"PHASE1","title":"Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-10-04","conditions":["Anesthesia","Tooth Extraction"],"enrollment":73,"completionDate":"2024-06-10"},{"nctId":"NCT06166849","phase":"NA","title":"Clinical Evaluation of an Experimental Remineralization Product","status":"COMPLETED","sponsor":"Ivoclar Vivadent AG","startDate":"2023-03-28","conditions":["White Spot Lesion"],"enrollment":43,"completionDate":"2025-03-11"},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":["Lumbar Radiculopathy","Sciatica","Back Pain With Radiation"],"enrollment":150,"completionDate":"2027-05"},{"nctId":"NCT07495605","phase":"NA","title":"Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp.","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-22","conditions":["Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":["Multiple Myeloma"],"enrollment":28,"completionDate":"2027-06-01"},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":["Advanced Solid Malignancies"],"enrollment":41,"completionDate":"2026-04-30"},{"nctId":"NCT05933499","phase":"PHASE2","title":"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-05","conditions":["Obesity"],"enrollment":63,"completionDate":"2029-03-31"},{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2026-03-19"},{"nctId":"NCT04969926","phase":"","title":"Natural History Study of Parathyroid Disorders","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-11-30","conditions":["Parathyroid Cancer","Primary Hyperparathyroidism","Pseudohypoparathyroidism","Inheritable Bone Diseases","Multiple Endocrine Neoplasia, Type 1"],"enrollment":3000,"completionDate":"2031-01-22"},{"nctId":"NCT07244991","phase":"NA","title":"Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2026-01-04","conditions":["Dental Caries","Streptococcus Mutans","Tooth Demineralization","Orthodontic Appliances, Fixed"],"enrollment":200,"completionDate":"2027-11"},{"nctId":"NCT05811403","phase":"NA","title":"Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2023-07-01","conditions":["Irreversible Pulpitis"],"enrollment":64,"completionDate":"2026-06-30"},{"nctId":"NCT07431866","phase":"PHASE1","title":"A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-18","conditions":["Healthy"],"enrollment":39,"completionDate":"2026-06-07"},{"nctId":"NCT06235567","phase":"PHASE1,PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2028-12-10"},{"nctId":"NCT06524921","phase":"NA","title":"Biodentine Pulpotomy vs Metapex Pulpectomy in Primary Molars: Clinical & Radiographic Comparison of Outcomes in Irreversible Pulpitis Cases","status":"COMPLETED","sponsor":"Mohamed Ahmed Hamdi Abo El Yamin","startDate":"2024-10-01","conditions":["Dental Caries"],"enrollment":28,"completionDate":"2025-09-15"},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":810,"completionDate":"2033-11-30"},{"nctId":"NCT07491601","phase":"NA","title":"PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery\"","status":"RECRUITING","sponsor":"Nicolas Schlegel","startDate":"2025-01-08","conditions":["Postoperative Hypoparathyroidism","Postsurgical Hypoparathyroidism","Hypoparathyroidism Post-surgical"],"enrollment":336,"completionDate":"2029-12-31"},{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":["End Stage Renal Disease"],"enrollment":170,"completionDate":"2027-04-28"},{"nctId":"NCT07477171","phase":"NA","title":"Mineral Trioxide Aggregate (MTA) vs Gutta-Percha for Non-Surgical Endodontic Retreatment in Teeth With Apical Lesions","status":"NOT_YET_RECRUITING","sponsor":"University of Santiago de Compostela","startDate":"2026-03","conditions":["Periapical Diseases","Root Canal Therapy","Mineral Trioxide Aggregate (MTA)"],"enrollment":58,"completionDate":"2027-04"},{"nctId":"NCT07488858","phase":"NA","title":"Thyroidectomy: Microscopic Versus Conventional","status":"COMPLETED","sponsor":"Shahida Islam Medical Complex","startDate":"2025-12-16","conditions":["Thyroid Cancer","Thyroid Surgeries"],"enrollment":74,"completionDate":"2026-03-15"},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":["Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Oligometastatic Esophageal Adenocarcinoma","Oligometastatic Gastric Adenocarcinoma","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8"],"enrollment":314,"completionDate":"2028-03-31"},{"nctId":"NCT03969329","phase":"PHASE3","title":"A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis","status":"RECRUITING","sponsor":"Amgen","startDate":"2019-12-20","conditions":["Secondary Hyperparathyroidism"],"enrollment":24,"completionDate":"2027-06-30"},{"nctId":"NCT04930237","phase":"","title":"RELISTOR's Effects on Opioid-Induced Constipation","status":"WITHDRAWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":["OIC"],"enrollment":0,"completionDate":"2022-04-22"},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":176,"completionDate":"2026-12-31"},{"nctId":"NCT05850091","phase":"PHASE4","title":"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-07","conditions":["Coronary Artery Disease"],"enrollment":200,"completionDate":"2027-05-01"},{"nctId":"NCT01297764","phase":"PHASE1,PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-07"},{"nctId":"NCT06156293","phase":"NA","title":"Prevention of Insomnia Using a Stepped Care Model in Adults","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-12-01","conditions":["Sleep Disturbance"],"enrollment":1016,"completionDate":"2026-12-31"},{"nctId":"NCT06276270","phase":"NA","title":"Multi-centre, Open-label, First-in-man Study With Mucopad HA","status":"COMPLETED","sponsor":"Contipro Pharma a.s.","startDate":"2023-12-12","conditions":["Oral Mucositis"],"enrollment":50,"completionDate":"2024-11-30"},{"nctId":"NCT07485296","phase":"PHASE2","title":"Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-01-27","conditions":["Head & Neck Squamous Cell Carcinoma"],"enrollment":45,"completionDate":"2032-12"},{"nctId":"NCT07486570","phase":"NA","title":"Anastomotic Leakage Prevention by Endovascular Stenting of the Superior Mesenteric Artery","status":"RECRUITING","sponsor":"Medisch Spectrum Twente","startDate":"2026-02-01","conditions":["Mesenteric Vascular Disease","Colorectal Surgery","Preventive Intervention"],"enrollment":360,"completionDate":"2029-01-01"},{"nctId":"NCT05722067","phase":"NA","title":"Improvement of Fertilization Rate and Embryo Quality by Treating Calcium Ionophore in IVF Patients: a Sibling Oocyte Control Study","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-01-01","conditions":["IVF","Infertility","Artificial Oocyte Activation"],"enrollment":68,"completionDate":"2025-06-30"},{"nctId":"NCT05916950","phase":"NA","title":"The THOR IDE Study","status":"RECRUITING","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2024-10-29","conditions":["Peripheral Artery Disease","Peripheral Artery Stenosis","Peripheral Artery Calcification","PAD"],"enrollment":155,"completionDate":"2027-12"},{"nctId":"NCT02773030","phase":"PHASE1,PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":["Multiple Myeloma"],"enrollment":466,"completionDate":"2028-07-28"},{"nctId":"NCT07486453","phase":"PHASE1","title":"Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2026-03-09","conditions":["Primary Hypertension"],"enrollment":60,"completionDate":"2026-04-25"},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":["Hyperlipidemia"],"enrollment":975,"completionDate":"2027-03-01"},{"nctId":"NCT04604301","phase":"NA","title":"Celtra Quatro Crown Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan","startDate":"2020-09-24","conditions":["Fractured Tooth","Decayed Tooth","Unsatisfactory Restoration of Tooth"],"enrollment":48,"completionDate":"2027-11-01"},{"nctId":"NCT03704350","phase":"NA","title":"Influence of Obesity on Endogenous Oxalate Synthesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2019-05-24","conditions":["Kidney Stone"],"enrollment":40,"completionDate":"2026-12-01"},{"nctId":"NCT07484035","phase":"NA","title":"Safety and Efficacy Evaluation of an Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy (CMPA)","status":"NOT_YET_RECRUITING","sponsor":"Heilongjiang Feihe Dairy Co. Ltd.","startDate":"2026-03-05","conditions":["Cow's Milk Protein Allergy (CMPA)"],"enrollment":124,"completionDate":"2026-07-31"},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":["Colorectal Neoplasms"],"enrollment":1000,"completionDate":"2032-01-30"},{"nctId":"NCT07204977","phase":"PHASE1","title":"Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-02-02","conditions":["Amyotrophic Lateral Sclerosis","Motor Neuron Disease"],"enrollment":30,"completionDate":"2028-09-30"},{"nctId":"NCT06673888","phase":"NA","title":"Assessment of Alkasite Restorative Material Versus Resin Modified Glass Ionomer in Class V Cavities: A Clinical Trial","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-12-01","conditions":["Class V Dental Caries"],"enrollment":50,"completionDate":"2025-12-01"},{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":["Coronary Atherosclerosis","Mixed Dyslipidemia","Hypercholesterolemia"],"enrollment":103,"completionDate":"2028-10-02"},{"nctId":"NCT06782100","phase":"","title":"MRI Guided Management of Occlusive Peripheral Arterial Disease","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-07-01","conditions":["Peripheral Vascular Diseases"],"enrollment":175,"completionDate":"2029-06"},{"nctId":"NCT07300280","phase":"PHASE1","title":"A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-29","conditions":["Healthy"],"enrollment":60,"completionDate":"2026-07-22"},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":["Marginal Zone Lymphoma(MZL)"],"enrollment":65,"completionDate":"2029-10-02"},{"nctId":"NCT06683833","phase":"PHASE4","title":"Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-09-03","conditions":["Deep Caries","Indirect Pulp Capping","Mineral Trioxide Aggregate (MTA)","Calcium Hydroxide","Biodentine","Patient Reported Outcome Measures"],"enrollment":35,"completionDate":"2026-07-03"},{"nctId":"NCT06013722","phase":"NA","title":"Strategy for Unstable Coronary Plaque in Patients Presenting to Emergency Department for Chest Pain Suspected of Coronary Artery Disease","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2024-03-18","conditions":["Atherosclerosis"],"enrollment":250,"completionDate":"2028-03"},{"nctId":"NCT07385781","phase":"","title":"Psychosomatic Symptoms in Patients With Myofascial Pain and Temporomandibular Joint Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-03-01","conditions":["Psychosomatic Symptoms","Temporomandibular Disorder (TMD)"],"enrollment":300,"completionDate":"2026-08-30"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT07239739","phase":"NA","title":"Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Faiz ur rahman","startDate":"2026-06-15","conditions":["Periapical Lesion","Periapical Periodontitis"],"enrollment":62,"completionDate":"2026-12-15"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":["Esophageal Cancer, Squamous Cell"],"enrollment":15,"completionDate":"2022-07-05"},{"nctId":"NCT06207123","phase":"PHASE1,PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":["Acute Leukemia","Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":15,"completionDate":"2026-12-01"},{"nctId":"NCT04661540","phase":"PHASE2","title":"A Study of Auxora in Patients With Critical COVID-19 Pneumonia","status":"TERMINATED","sponsor":"CalciMedica, Inc.","startDate":"2021-03-02","conditions":["Pneumonia"],"enrollment":10,"completionDate":"2021-12-21"},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":["Multiple Myeloma"],"enrollment":75,"completionDate":"2031-03"},{"nctId":"NCT04143711","phase":"PHASE1,PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":["Solid Tumor, Adult"],"enrollment":270,"completionDate":"2025-12-05"},{"nctId":"NCT07218900","phase":"PHASE2","title":"A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-13","conditions":["Dyslipidaemia"],"enrollment":76,"completionDate":"2026-09-30"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT04789733","phase":"NA","title":"The GUARDIAN Pilot Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-04-27","conditions":["General Surgery"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT06896669","phase":"NA","title":"Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-28","conditions":["Diabetes Mellitus, Gestational"],"enrollment":60,"completionDate":"2026-03-05"},{"nctId":"NCT06712719","phase":"NA","title":"Effects of Dietary Phosphorus on Phosphorus and Calcium Whole-Body Balance and Kinetics in Moderate CKD","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-05-01","conditions":["CKD"],"enrollment":14,"completionDate":"2027-05-28"},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":525,"completionDate":"2029-07-25"},{"nctId":"NCT05958342","phase":"PHASE2","title":"CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial","status":"RECRUITING","sponsor":"Jason Sperry","startDate":"2024-06-30","conditions":["Trauma","Hemorrhage"],"enrollment":1050,"completionDate":"2028-03"},{"nctId":"NCT06469944","phase":"PHASE1,PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":["Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer"],"enrollment":160,"completionDate":"2029-09-12"},{"nctId":"NCT05739383","phase":"PHASE3","title":"A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-09","conditions":["Primary Prevention of Atherosclerotic Cardiovascular Disease"],"enrollment":14078,"completionDate":"2029-04-16"},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":["Multiple Myeloma"],"enrollment":30,"completionDate":"2026-07"},{"nctId":"NCT07461649","phase":"NA","title":"Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting Conditions","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Credit Pharmaceutical Co., Ltd.","startDate":"2026-03-15","conditions":["Bioavailability and Pharmacokinetics"],"enrollment":32,"completionDate":"2026-05-10"},{"nctId":"NCT07460960","phase":"PHASE2","title":"TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","status":"RECRUITING","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2026-03-05","conditions":["Erectile Dysfunction Due to Arterial Disease","Atheroscleroses","Erectile Disfunction","Endothelial Dysfunction","Androgen Profile","Testosterone"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT05081999","phase":"PHASE4","title":"De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2023-01-30","conditions":["Stable Ischemic Heart Disease","Coronary Artery Disease","Beta-blocker Therapy"],"enrollment":59,"completionDate":"2026-12-31"},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":30,"completionDate":"2029-03-11"},{"nctId":"NCT06734559","phase":"NA","title":"Assessment of Masseter Muscle With Ultrasonography","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harran University","startDate":"2025-01-30","conditions":["Acute Apical Periodontitis of Pulpal Origin"],"enrollment":60,"completionDate":"2026-03-11"},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":30,"completionDate":"2031-12-31"},{"nctId":"NCT07471516","phase":"PHASE1,PHASE2","title":"Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-25","conditions":["Congenital Dyserythropoietic Anemia (CDA)"],"enrollment":2,"completionDate":"2027-08-12"},{"nctId":"NCT05664477","phase":"PHASE2","title":"PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roberta Brinton","startDate":"2024-01-10","conditions":["Menopause","Cognitive Change","Brain Disorder, Metabolic"],"enrollment":100,"completionDate":"2027-01-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Solution","formulations":[{"form":"SOLUTION","route":"ORAL","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"Y882YXF34X","RXCUI":"359296","SPL_ID":"7749772b-1a26-4b2e-b97d-3ee29611d035","chemblId":"CHEMBL1200668"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2022-","companyName":"Fresenius Kabi Usa","relationship":"Original Developer"},{"period":"present","companyName":"Fresenius Medcl Care","relationship":"Current Owner"}],"publicationCount":475317,"therapeuticAreas":["Nephrology"],"applicationNumber":"ANDA214623","biosimilarFilings":[],"originalDeveloper":"Fresenius Kabi Usa","recentPublications":[{"date":"2026 Mar 30","pmid":"41913078","title":"Stinging nettle leaf powder: Functional, nutritional, antinutritional qualities and acceptability of a developed savoury snack.","journal":"Journal of the science of food and agriculture"},{"date":"2026 Mar 31","pmid":"41913003","title":"Mechanical performance optimization of CaCO₃-modified fly ash-based hybrid geopolymer concrete using Taguchi methodology.","journal":"Environmental science and pollution research international"},{"date":"2026 Mar 30","pmid":"41912823","title":"Calcium Signaling Modulator 4-MPTC Reduces Proliferative and Migration Activities of MDA-MB-468 Breast Cancer Cells.","journal":"Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections"},{"date":"2026 Mar 31","pmid":"41912655","title":"Repurposing lurasidone to alleviate doxorubicin-induced cardiotoxicity and neurotoxicity via BDNF/TrkB/PI3K/Akt/CREB and miR-34a-5p/PGC-1α pathways.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Mar 30","pmid":"41912643","title":"Using machine learning algorithms to predict MACE in peritoneal dialysis patients.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturers":13,"_genericFilersChecked":true,"genericManufacturerList":["Amneal Pharms","Chartwell Molecular","Chartwell Rx","Cypress Pharm","Heritage Pharms Inc","Hikma","Invagen Pharms","Lotus Pharm Co Ltd","Lupin Ltd","Mpp Pharma","Padagis Us","Square Pharms","Suven Pharms"],"status":"approved","companyName":"Fresenius Medcl Care","companyId":"fresenius-medcl-care","modality":"Small molecule","firstApprovalDate":"2022","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1984-02-28T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA018494"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-02-22T00:00:00.000Z","mah":"FRESENIUS MEDCL","brand_name_local":null,"application_number":"NDA018883"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-05-31T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA089384"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-07-27T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA207226"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-11T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":null,"application_number":"ANDA206047"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":39,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:25:44.661182+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}